

16569
020504
U.S.PTO

UTILITY PATENT APPLICATION TRANSMITTAL		CERTIFICATE UNDER 37 C.F.R. 1.10	
(Only for new nonprovisional application under 37 CFR 1.53(b))		Docket No. IVD 1000-3	
APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents.</i>		ADDRESS TO: Commissioner for Patents Box Patent Application Washington, DC 20231	
1. <input checked="" type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i>			
2. <input checked="" type="checkbox"/> Specification Total Pages <u>36</u> <i>(preferred arrangement set forth below)</i> <ul style="list-style-type: none"> - Descriptive Title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Sequence Listing or a Table Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings <i>(if filed)</i> - Detailed Description - Claim(s) - Abstract of the Disclosure 			
3. <input type="checkbox"/> Drawing(s) <i>(35 USC 113)</i> Total Sheets <u> </u>			
4. <input checked="" type="checkbox"/> Oath or Declaration/ Power of Attorney Total Sheets <u>3</u> <ul style="list-style-type: none"> a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application <i>(37 CFR 1.63(d))</i> <i>(for continuation/divisional with Box 16 completed)</i> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 			
5. <input type="checkbox"/> Application Data Sheet <i>(See 37 CFR 1.76)</i>			
6. <input type="checkbox"/> CD-Rom or CD-R, Large Table or Computer Program <i>(Appendix)</i>			
7. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i> <ul style="list-style-type: none"> a. <input type="checkbox"/> Computer Readable Form (CFR) b. <input type="checkbox"/> Paper copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies 			
ACCOMPANYING APPLICATION PARTS			
8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))			
9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney			
10. <input type="checkbox"/> English Translation Document <i>(if applicable)</i>			
11. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations			
12. <input checked="" type="checkbox"/> Preliminary Amendment			
13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>			
14. <input type="checkbox"/> Request and Certification under 35 U.S.C. 122(b)(2)(B)(i)			
15. <input checked="" type="checkbox"/> Other: <u>Citation of References</u>			
16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76:			
<input type="checkbox"/> Continuation <input checked="" type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application no: <u>10/044,223</u>			
Prior Application Information:		Examiner: <u>Jane T. Fan</u>	Group Art Unit: <u>1625</u>
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.			
17. CORRESPONDENCE ADDRESS			
<input checked="" type="checkbox"/> Customer Number or Bar Code Label		27546	or <input checked="" type="checkbox"/> Correspondence address below
Paul E. Dupont Sanofi-Synthelab Inc. 9 Great Valley Parkway Malvern, PA 19355 Telephone No.: (610) 889-6338 Facsimile No.: (610) 889-8799		Respectfully submitted,  Paul E. Dupont Reg. No. 27,438	

16834 U.S.PTO
10/07/2004

020504

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Divisional Under 37 C.F.R. 1.53(b)
 Application of: Bono-Colombie et al.

Prior Application Serial No.: 10/044,223

Prior Filing Date: November 20, 2001

Group Art Unit: 1625

Examiner: Jane T. Fan

For: USE OF 4-SUBSTITUTED TETRAHYDRO-PYRIDINES FOR MAKING MEDICINES ACTING ON TGF-BETA 1

Mail Stop Patent Application
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label Number: EL676469648US

Date of Deposit: February 5, 2004

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Name

Geraldine A. Stee

FEE TRANSMITTAL FORM

The filing fee for the above-identified has been calculated as shown below:

		<u>Claims as Filed</u>		Rate	Basic Fee
	Number Filed	Number Extra			
Total Claims	4	-20 =	0	X \$ 18.00 =	0.00
Independent Claims	2	- 3 =	4	X \$ 86.00 =	0.00
Multiple dependent claims(s), if any				\$290.00 =	0.00
Total Filing Fee:					\$770.00

Please charge the following fees to Deposit Account No. 19-0091.

Filing Fee of \$ 770.00
 Assignment recordal fee of \$

Please charge any additional fees under 37 CFR 1.16 which may be required, or credit any overpayment, to Deposit Account No. 19-0091. A **duplicate copy** of this sheet is enclosed.

This application is being filed by "Express Mail" as of the date of this letter pursuant to 37 CFR 1.10(b).

Date: 2/5/04

Address:

Patent Department
 Sanofi-Synthelabo Inc.
 9 Great Valley Parkway
 Malvern, PA 19355
 Tele: (610) 889-6338
 Fax: (610) 889-8799

Paul E. Dupont
 Paul E. Dupont
 Reg. No. 27,438

Application of: Bono-Colombie et al.

Docket No.: IVD 1000-3

Divisional of U.S. Application Serial No. 10/044,223

FOR: USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR
MAKING MEDICINES ACTING ON TGF-BETA 1


CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label No.: EL676469648US

Date of Deposit: February 5, 2004

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to:

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Signature

ENGLISH TRANSLATION OF INTERNATIONAL PATENT
APPLICATION PCT/FR98/01000
filed on
20 May 1998

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label No.: EL676469648US

Date of Deposit: February 5, 2004

I hereby certify that the attached English Translation is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to: Mail Stop Patent Applications, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Bernadine A. Shue
Signature